AbbVie puts $161M into new R&D site in Germany, will add 300 jobs

AbbVie is investing around €150 million ($161 million) into an R&D site at its Rhineland-Palatinate location in Germany which it expects to complete in 2027, the company announced this week.

At a site that employs more than 2,000 already, the new building will house more than 300 employees in oncology, neuroscience and immunology. It adds to the approximately €250 million ($269 million) AbbVie has invested into Germany since 2020.

Martin Gastens

Martin Gastens, vice president of biologics drug product development and managing director for R&D at AbbVie Germany, wrote in a statement that the construction of what the company is calling the “LUnA” research building “is much more than a €150 million investment in cutting-edge infrastructure.”

“We are creating attractive working conditions for our top scientists and attracting new talent so that we can conduct cutting-edge research at our site in…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks